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Neural progenitor cell (NPC) therapy is considered
a promising treatment modality for multiple sclerosis
(MS), potentially acting through neural repair. Here,
we showed that intravenous administration of NPCs
ameliorated experimental autoimmune encephalo-
myelitis (EAE) by selectively inhibiting pathogenic T
helper 17 (Th17) cell differentiation. Leukemia inhibi-
tory factor (LIF) produced by NPCs was responsible
for the observed EAE suppression. Through the
inducible LIF receptor expression, LIF inhibited the
differentiation of Th17 cells in EAE mice and that
fromMS subjects. At the molecular level, LIF exerted
an opposing effect on interleukin 6 (IL-6)-induced
signal transducer and activator of transcription 3
(STAT3) phosphorylation required for Th17 cell
differentiation by triggering a signaling cascade
that activated extracellular signal-regulated MAP
kinase (ERK) and upregulated suppressor of cyto-
kine signaling 3 (SOCS3) expression. This study
reveals a critical role for LIF in regulating Th17 cell
differentiation and provides insights into the mecha-
nisms of action of NPC therapy in MS.INTRODUCTION
Although the etiology and pathogenesis of multiple sclerosis
(MS) remain elusive, it is generally considered an autoimmune
disease of the central nervous system (CNS) that is character-
ized by multifocal inflammation, demyelination, and axonal loss
and degeneration (Sospedra and Martin, 2005). Increasing
evidence indicates that T helper cells with pathogenic potential
(mainly interferon-g [IFN-g]-producing T helper 1 [Th1] cells
and interleukin-17 [IL-17]-producing Th17 cells) play a key role
in the inflammatory and demyelinating pathology, whereas regu-latory T (Treg) cells function to keep the autoimmune response in
check (Bettelli et al., 2006; Ja¨ger et al., 2009).
Th17 cells have been found in the brain lesions of patients with
MS, and elevated amounts of IL-17 have been reported in their
serum and cerebrospinal fluid (Kebir et al., 2007; Tzartos et al.,
2008). The critical role of Th17 cells in the disease process has
been elegantly demonstrated in experimental autoimmune
encephalomyelitis (EAE), an animal model of MS (Hemmer
et al., 2006). Genetic deficiency of IL-17 leads to resistance to
EAE, as shown by delayed onset and decreased disease
severity, whereas adoptive transfer of Th17 cells derived from
EAE mice into naive recipients leads to the development of the
disease (El-behi et al., 2010; Furuzawa-Carballeda et al., 2007;
Langrish et al., 2005). There is growing evidence for the role of
Th17 cells in the pathogenesis of autoimmune disease (Dong,
2008; Komiyama et al., 2006). Th17 cell differentiation is induced
by IL-6 and IL-21 in the presence of transforming growth factor-b
(TGF-b) through the activation of STAT3 and retinoic-acid-
receptor-related orphan receptors a and gt (RORa and RORgt,
respectively) (Ivanov et al., 2006; Manel et al., 2008; Stockinger
and Veldhoen, 2007; Yang et al., 2008b). The survival and
expansion of committed Th17 cells require IL-23 through
STAT3 and IL-7 through STAT5 (Chen et al., 2007; Harris et al.,
2007; Liu et al., 2010; Mathur et al., 2007). SOCS3 serves as
an important negative regulator of Th17 cells; Socs3/ T cells
exhibited greatly increased Th17 cell differentiation and
cytokine expression (Chen et al., 2006).
Recently, neural progenitor cell (NPC) transplantation has
been extensively studied as a novel therapeutic approach for
MS because NPCs are capable of differentiating into oligoden-
drocytes and repairing injured myelin tissue (Pluchino et al.,
2003). Prompted by this therapeutic potential, researchers
have conducted experiments in EAE mice to evaluate the
efficacy of NPC treatment. It has been shown that NPCs were
indeed capable of differentiating into oligodendrocytes in
lesioned areas of the brain and spinal cord in EAE mice after
direct CNS delivery and, to some degree, intravenous delivery
(Ben-Hur et al., 2003; Pluchino et al., 2003). However, there is
also evidence suggesting that, in addition to their capacity for
myelin repair, NPCs have anti-inflammatory properties in theImmunity 35, 273–284, August 26, 2011 ª2011 Elsevier Inc. 273
Figure 1. Amelioration of EAE by Intravenous Administration of NPCs
(A) Clinical scores of EAE mice treated with NPCs (n = 9) or PBS (n = 10) intravenously at the day of immunization as indicated by the arrow.
(B) Representative H&E-stained or Luxol fast blue-stained spinal cord sections from treated or control EAE mice harvested on day 28 postimmunization. Scale
bars represent 100 mm.
(C) Splenocytes derived from treated or control EAE mice were restimulated with MOG35–55 (20 mg/ml) or ConA (2 mg/ml) for 72 hr. Proliferation was examined by
[3H]-thymidine incorporation. Stimulation index shown on the y-axis is calculated as C.P.M. of experiment group/C.P.M. of medium control.
(D) Cytokines production by splenocytes restimulated with MOG35–55 (20 mg/ml) were determined by ELISAs.
(E) Intracellular staining of IL-17, IFN-g, and Foxp3 in CD4+ T cells derived from the spleen (left) or CNS (right) of treated or control EAE mice.
*p < 0.05 (two-tailed Student’s t test). Data are representative of three independent experiments (mean and SEM in A, C, and D).
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Pluchino et al., 2005). NPCs produce a variety of cytokines and
neurotrophins, including tumor necrosis factor-a (TNF-a),
brain-derived neurotrophic factor (BDNF), bone morphogenetic
protein 4 (BMP-4), and leukemia inhibitory factor (LIF), some of
which exhibit immunoregulatory activity by inhibiting inflamma-
tory responses (Makar et al., 2008; Pluchino et al., 2009).
However, the exact mechanism underlying the treatment
efficacy of NPCs in EAE is not completely understood. In
particular, the extent to which the immunoregulatory pro-
perties of NPCs contribute to their treatment efficacy in EAE is
unknown.
This study was prompted by our observations that NPCs did
not accumulate in the CNS upon intravenous administration
and that the same EAE efficacy could be achieved with irradiated
NPCs or NPC-derived supernatant. We addressed this molec-
ular mechanism starting from the critical finding that NPCs
specifically inhibited pathogenic Th17 cell differentiation through
secreted factor(s). By focusing on the critical factor(s) respon-
sible for the immunoregulatory properties of NPCs both in vitro
and in vivo, we provided compelling evidence identifying LIF as
the key factor directly accountable for the treatment efficacy of
NPCs in EAE through the inhibition of Th17 cell differentiation.
In addition, we elucidated signaling mechanism wherein LIF
antagonized IL-6-induced Th17 cell differentiation, through the274 Immunity 35, 273–284, August 26, 2011 ª2011 Elsevier Inc.activation of ERK and SOCS3 expression and the subsequent
inhibition of STAT3 phosphorylation. This study has important
implications in the understanding of LIF biology and the develop-
ment of MS therapy.
RESULTS
Amelioration of EAE and Selective Reduction
of Th17 Cells by NPC Treatment
First, we validated the potential of mouse embryonic stem cell
(ESC)-derived NPCs to differentiate into the three neural cell line-
ages, i.e., neurons, oligodendrocytes, and astrocytes (see Fig-
ure S1A available online). A single injection of mouse NPCs
(2 3 106 cells per mouse) was intravenously administered to
mice on the day of immunization. The treatment resulted in
a substantial delay of the disease onset and a marked reduction
in EAE severity accompanied by decreased inflammation and
demyelination in the affected spinal cord compared to control
mice (Figures 1A and 1B). Administration of NPCs via a thera-
peutic protocol was also efficacious in the amelioration of EAE
(Figure S1B). To track the distribution pattern and kinetics of
transplanted NPCs, we injected NPCs labeled with fluorescent
Q-dot nanocrystals (QDs) and enumerated the labeled NPCs in
the indicated tissues throughout the course of EAE (days 2, 7,
14, 21, and 30). Detailed fluorescence microscopic analyses of
Immunity
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cells were rarely detectable in the CNS sections. In contrast,
labeled NPCs were detected predominantly in the spleen and
lymph nodes and the cell number declined over a period of 15
to 20 days (Figure S1C).
The lack of injected NPCs in CNS prompted us to investigate
the possibility of a peripheral anti-inflammatory mechanism in
the observed therapeutic efficacy of NPCs. We observed that
MOG35-55-stimulated T cell reactivity was markedly inhibited in
the treated EAE mice, whereas the T cell response to ConA
was not affected (Figure 1C). Furthermore, we found that the
overall activation, proliferation, and survival of CD4+ T cells
and the function of antigen-presenting cells (APCs) were not
affected in NPC-treated EAE mice (Figure S1D). Among a panel
of pro- and anti-inflammatory cytokines tested, the production of
IL-17, but not other cytokines, by MOG35-55-stimulated T cells
was significantly reduced in NPC-treated compared with control
EAE mice (0.41 ± 0.07 ng/ml versus 0.74 ± 0.09 ng/ml, p < 0.05;
Figure 1D). In parallel, the frequency of effector or infiltrating
Th17 cells was markedly decreased in both the spleen and the
CNS of the treated versus control EAE mice (spleen: 5.40% ±
2.32% versus 10.22% ± 2.46%, p < 0.01; spinal cord: 8.15% ±
2.53% versus 15.87% ± 4.07%, p < 0.01), whereas the
percentage of Th1 cells (spleen: 8.54% ± 2.53% versus
9.88% ± 3.70%, p > 0.05; spinal cord: 31.07% ± 4.03% versus
28.23% ± 5.93%, p > 0.05) or Treg cells (spleen: 16.28% ±
3.54% versus 15.72% ± 1.91%, p > 0.05; spinal cord:
26.80% ± 6.42% versus 23.83% ± 4.92%, p > 0.05) was not
affected (Figure 1E). In addition, there was no difference in the
regulatory function of Treg cells in NPC-treated and control
EAE mice (Figure S1E). These results indicate that intravenously
administered NPCs predominantly reside in the peripheral
lymphoid tissues but not in the CNS and that they ameliorate
EAE by inhibiting Th17 cell differentiation.
Inhibition of Th17 Cell Differentiation
by Soluble Factor(s) Secreted by NPCs
To elucidate the mechanism of action of NPCs, we injected irra-
diated NPCs intravenously into EAEmice. Irradiated NPCsmain-
tained their ability to secrete cytokines and neurotrophins but
were unable to undergo lineage-specific differentiation (data
not shown). NPC-derived supernatant was intraperitoneally
administered into EAE mice. Both treatments achieved the
same therapeutic efficacy as that of nonirradiated NPCs in inhib-
iting EAE severity as well as in reducing the frequency of Th17
cells in the spleen and the CNS (Figures 2A and 2B). The findings
further support the possibility that the therapeutic efficacy of
NPCs is mediated by secreted factor(s) that modulate peripheral
immunoregulation rather than a direct effect on myelin repair.
Next, we examined the effect of NPC supernatant on the
differentiation of Th1, Th17, and Treg cells from purified
CD4+CD25 T cells. Addition of NPC supernatant markedly sup-
pressed the differentiation of Th17 cells in a dose-dependent
manner (Figure 2C) but did not affect the differentiation of Th1
cells or Treg cells (Figure 2D). Consistently, injection of NPC
supernatant resulted in the inhibition of Th17 cell differentiation
in a Th17 cell-driven EAE model with Ifng/ (Figure 2E) or
Stat1/mice (data not shown). These findings strongly support
a peripheral mechanism of NPC therapy that acts throughsecreted factor(s) to selectively inhibit Th17 cell differentiation,
conferring EAE treatment efficacy.
Role of LIF in NPC-Mediated Suppression of Th17 Cell
Differentiation and EAE Efficacy
We then focused on identifying the secreted factor(s) respon-
sible for the observed effects of NPCs. To this end, a panel of
cytokines and neurotrophins known to be produced by NPCs
were tested for their ability to suppress in vitro Th17 cell differen-
tiation. The results led to the discovery of LIF as the primary
factor for this property. First, we revealed that fully differentiated
NPCs produced a substantial amount of LIF (0.84 ± 0.05 ng/ml)
during differentiation from ESCs. Second, the inhibitory effect of
NPC supernatant on Th17 cell differentiation in vitro was almost
completely abolished by addition of a LIF-neutralizing antibody
(Figure 3A). Pretreatment of NPC supernatant with the LIF-
neutralizing antibody abrogated the therapeutic efficacy in EAE
mice, with an associated increase in the percentage of Th17 cells
in the spleen and CNS (Figure 3B). Correspondingly, the admin-
istration of a LIF neutralizing antibody into NPC-treated EAE
mice completely abolished EAE efficacy of NPC treatment
(Figure S2A).
Furthermore, direct administration of recombinant mouse LIF
led to markedly reduced EAE severity (Figure 3C) and decreased
percentage and absolute number of Th17 cells in the spleen and
CNS of the treated mice (Figure 3D), whereas it had no effect on
Th1 or Treg cells. The effect of LIF in EAE mice was also seen
with a therapeutic protocol (Figure S2B). Consistently, LIF treat-
ment selectively inhibited in vitro differentiation of Th17 cells in
a dose-dependent manner (Figure S2C) but not the differentia-
tion of Th1 or Treg cells (Figure 3E). We then assessed the
expression of the LIF receptor (LIFR) and its dynamics in the
context of Th17 cell differentiation in vivo and in vitro. The results
showed that LIFR was not expressed on resting CD4+ T cells in
naive mice and its expression rose from less than 1% on resting
T cells to more than 80% on Th17 cells both in EAE mice and
during in vitro Th17 cell differentiation (Figure 3F). Taken
together, these data indicate that LIF is responsible for both
the inhibition of Th17 cell differentiation and the observed
efficacy of NPCs in EAE.
Inhibition of Th17 Cell Differentiation by LIF through
Upregulation of ERK and SOCS3 and Downregulation
of STAT3 Phosphorylation
To delineate the molecular mechanism underlying the observed
inhibitory effect of LIF on Th17 cell differentiation, we assessed
the signaling activity of the JAK-STAT pathways, which are
critically involved in the differentiation of T helper subsets, in
CD4+ T cells derived from LIF-treated EAE mice. Among the
signaling molecules tested, the phosphorylation of JAK-2 and
STAT3 was inhibited in CD4+ T cells, whereas the phosphoryla-
tion of other STATs involved in Th1 or Th2 cell differentiation was
not altered (Figure 4A). This finding was confirmed by in vitro
experiments performed on CD4+ T cells under Th1, Th17, or
Th2 cell differentiation conditions (Figures 4B).
Next, we investigated the upstream signaling events involved
in the alteration of STAT3 phosphorylation by LIF. Upon LIF treat-
ment, SOCS3 expression was elevated in CD4+ T cells both
in vivo and in vitro (Figure 4C). The causal relationship betweenImmunity 35, 273–284, August 26, 2011 ª2011 Elsevier Inc. 275
Figure 2. Selective Inhibition of Th17 Cells by Factor(s) Secreted by NPCs
(A) Clinical scores (top) and intracellular staining of IL-17 and IFN-g in CD4+ T cells (bottom) from the spleen or CNS of EAE mice treated with NPCs (n = 7),
irradiated NPCs (n = 7), or PBS (n = 8) on the day of immunization.
(B) Clinical scores (top) and intracellular staining of IL-17 and IFN-g in CD4+ T cells (bottom) from the spleen or CNS of EAE mice treated with NPC supernatant
(NPCsup, n = 7) or control medium (n = 10) every other day, starting from the day of immunization.
(C) Purified CD4+CD25 T cells from naive mice were cultured under Th17 cell differentiation conditions in the presence of NPC supernatant at the indicated
dilutions. Intracellular staining of IL-17 and IFN-g were investigated by flow cytometry.
(D) CD4+CD25 T cells cultured under Th17, Th1, and Treg cell differentiation conditions in the absence or presence of NPC supernatant (1:10), followed by
intracellular staining of IL-17, IFN-g, and Foxp3. Averages are presented graphically on the right.
(E) Intracellular staining of IL-17 and IFN-g in CD4+ T cells derived from the spleen or CNS of Ifng/ mice immunized with MOG35–55 and treated with NPC
supernatant or control medium.
*p < 0.05 and **p < 0.01 (two-tailed Student’s t test). Data are representative of three independent experiments (mean and SEM in A, B, and D).
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tion in the context of LIF treatment was verified by employing
specific siRNAs. Specific gene targeting of Socs3 in CD4+
T cells increased the differentiation of Th17 cells in the absence
of LIF. It was evident that LIF treatment had little effect on Th17
cell differentiation and STAT3 phosphorylation when Socs3 was
targeted in CD4+ T cells, confirming a SOCS3-dependent mech-
anism (Figure 4D). To further investigate the pathway(s) involved
in LIF-induced upregulation of SOCS3 expression, we pre-
treated CD4+ T cells with pathway-specific inhibitors, including
PD98059 (a MEK1 inhibitor) and Stattic (a STAT3 inhibitor),
followed by culture under Th17 cell differentiation conditions in
the presence of LIF. The results showed that the MEK1-specific
inhibitor abrogated the effect of LIF on increased SOCS3 expres-
sion in CD4+ T cells whereas the addition of the STAT3 inhibitor
did not (Figure 4E). This was further validated with a genetic
approach where LIF treatment increased SOCS3 expression in276 Immunity 35, 273–284, August 26, 2011 ª2011 Elsevier Inc.Stat3/ and wild-type CD4+ T cells (Figure S3). Consistently,
we found that pretreatment of CD4+ T cells with a MEK1 inhibitor
led to a loss of the inhibitory effect of LIF on STAT3 phosphory-
lation and Th17 cell differentiation, indicating that the regulation
of SOCS3 by LIF involves the ERK signaling pathway (Figure 4E).
In addition, inhibition of Th17 cell differentiation and the associ-
ated changes in signaling activities (ERK, SOCS3, and STAT3)
were abrogated when LIFR expression was silenced with
specific siRNAs (Figures 4F and 4G). These results strongly
suggest that LIF signals through LIFRs to trigger an inhibitory
signaling cascade, opposing IL-6-induced STAT3 phosphoryla-
tion critical for Th17 cell differentiation. In addition, treatment of
NPC supernatant had similar effects on upregulation of ERK
phosphorylation and increased SOCS3 expression, which
correlated with impaired STAT3 phosphorylation and Th17 cell
differentiation and reversed by the addition of LIF-neutralizing
antibody (Figures 5A and 5B).
Figure 3. A Critical Role of LIF in the Inhibition of Th17 Cells
(A) Intracellular staining of IL-17 and IFN-g in CD4+ T cells cultured under Th17 cell differentiation conditions in the absence or presence of NPC supernatant or
NPC supernatant preincubated with a LIF-neutralizing antibody or an isotype control.
(B) NPC supernatant or control medium was preincubated with a LIF-neutralizing antibody or an isotype control and subsequently intraperitoneally injected into
EAE mice (n = 8 per groups) every other day, starting from the day of immunization. Clinical scores and intracellular staining of IL-17 and IFN-g in CD4+ T cells
derived from the spleen or CNS of these groups.
(C) Clinical scores of EAE mice treated intraperitoneally with LIF (10 mg/kg) (n = 6) or PBS (n = 6) daily, starting from the day of immunization.
(D) Intracellular staining of IL-17, IFN-g, and Foxp3 in CD4+ T cells from the spleen or CNS of EAE mice as described above. The absolute counts of CD4+IL-17+
(Th17) cells in the spleen or CNS are presented in the right panel.
(E) Flow cytometric analysis of Th17, Th1, and Treg cell subsets under individual lineage-specific conditions in the presence or absence of LIF (50 ng/ml).
(F) Surface expression of LIFR on naive CD4+ T cells or gated Th17 cells in CD4+ T cells that were derived from EAE mice at the indicated stage (top) or under
in vitro Th17 cell differentiation conditions at the indicated time point (bottom).
*p < 0.05 and **p < 0.01 (two-tailed Student’s t test). Data are representative of three independent experiments (mean and SEM in B, C, and D).
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CD4+ T Cells
The data described above suggest that LIF inhibited Th17 cell
differentiation by opposing STAT3 phosphorylation induced by
IL-6. Because LIF was previously shown to act independently
in upregulating STAT3 activity in some non-T cell types (Joly
et al., 2008; Setati et al., 2010; Slaets et al., 2008; Yu et al.,
2009), we examined the signaling characteristics of LIF in
CD4+ T cells in the absence of IL-6. To this end, CD4+ T cells
derived from Il6/ mice were used to exclude any confounding
effect resulting from endogenously produced IL-6. We demon-strated that unlike the constitutively expressed IL-6R, LIFR was
expressed on Il6/ CD4+ T cells only after TCR stimulation (Fig-
ure 6A). Consistently, LIF did not induce STAT3 phosphorylation
in Il6/ CD4+ T cells when LIFR was not expressed in the
absence of TCR stimulation (data not shown). However, once
the expression of LIFR was induced by TCR stimulation, LIF
was capable of inducing a low and transient STAT3 phosphory-
lation in Il6/ CD4+ T cells as compared to the strong and
sustained STAT3 phosphorylation triggered by IL-6 (Figure 6B).
As a result, exogenously added IL-6 stimulated Th17 cell differ-
entiation of Il6/CD4+ T cells in the presence of TGF-bwhereasImmunity 35, 273–284, August 26, 2011 ª2011 Elsevier Inc. 277
Figure 4. Mechanism Underlying the Inhibition of Th17 Cell Differentiation by LIF
(A) Immunoblot analysis of JAK-STATs in CD4+ T cells from lymph nodes of EAE mice treated with LIF or PBS.
(B) Flow cytometric analysis of the levels of phosphorylated STAT1, STAT3, and STAT6 in CD4+ T cells under in vitro Th1, Th17, or Th2 cell differentiation
conditions in the presence of LIF (50 ng/ml).
(C) SOCS3 expression determined by immunoblotting in CD4+ T cells from lymph nodes of LIF-treated or control EAE mice (left) or under in vitro Th17 cell
differentiation conditions in the presence of LIF (50 ng/ml) (right).
(D) Flow cytometric analysis of Th17 cell differentiation and STAT3 phosphorylation in CD4+ T cells transfected with Socs3-specific or control siRNAs under Th17
cell polarization conditions in the presence or absence of LIF (50 ng/ml).
Immunity
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Figure 5. Role of LIF in the Signaling Cascade
Triggered by NPC Supernatant in Th17 Cells
(A) CD4+CD25 T cells were cultured under Th17 cell
differentiation conditions in the presence of NPC
supernatant preincubated with a LIF-neutralizing
antibody or an isotype control. The percentage of
Th17 cells and the level of phosphorylated STAT3 in
CD4+ T cells were investigated by flow cytometry.
(B) Immunoblot analysis of phosphorylated STAT3,
phosphorylated ERK, and SOCS3 expression from the
same cell preparations as in (A).
Data are representative of four independent experi-
ments.
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Figure 6B), suggesting that this transient induction of STAT3
phosphorylation by LIF is not sufficient to induce Th17 cell
differentiation.
We hypothesized that LIF-induced STAT3 phosphorylation
could not sustain because the LIF signaling was subsequently
dominated by increased ERK and SOCS3 activities that sup-
pressed STAT3 phosphorylation. We investigated the transient
nature of LIF-induced STAT3 phosphorylation by measuring(E) Purified CD4+ T cells were preincubated with the indicated inhibitors and cultured in the presence or a
conditions. Immunoblotting analysis of SOCS3 expression (top) and flow cytometric analysis of the perc
STAT3 (bottom) in these CD4+ T cells.
(F) Purified CD4+ T cells were transfected with Lifr-specific or control siRNAs and subsequently cultured un
of LIF (50 ng/ml). LIFR expression was analyzed by real-time PCR and flow cytometry.
(G) The percentage of Th17 cells and the level of phosphorylated STAT3 by intracellular staining (top) and
immunoblotting (bottom) were analyzed from the same cell preparations as in (F).
*p < 0.05 and **p < 0.01 (two-tailed Student’s t test). Data are representative of four independent experi
Immunity 35, 273–the activities of ERK and SOCS3 in relation
to STAT3 phosphorylation at both the early
(30 min) and the later (4 to 24 hr) time points
after LIF treatment. The initial STAT3 phos-
phorylation at the early time point corre-
sponded to minimal SOCS3 activity, and its
phosphorylation level decreased along with
progressive increases in both ERK and
SOCS activity at the later time points (Fig-
ure 6C). Correspondingly, when SOCS3
expression was silenced with specific
siRNAs, LIF-induced STAT3 sustained
throughout (Figure 6D). Taken together, as
in non-T cells, LIF also induces STAT3
phosphorylation in CD4+ T cells in the
absence of IL-6. However, the failure of the
initial STAT3 phosphorylation to persist is
attributable to the activity of SOCS3
signaling initiated by LIF.
Inhibition of Human Th17 Cell
Differentiation by NPC Supernatant
and Recombinant LIF
A significant amount of LIF was secreted
by human NPCs in the culture (0.72 ±
0.07 ng/ml at 72 hr, p < 0.01; Figure 7A). To
determine the effect of LIF on human Th17cell development, we first induced Th17 cell differentiation of
purified CD4+CD25CD45RA+ T cells from healthy individuals in
the presence of human NPC supernatant. Addition of the NPC
supernatant inhibited Th17 cell differentiation and STAT3
phosphorylation in a dose-dependent manner, which was
abolished by the addition of human LIF-neutralizing antibody
(Figures 7B and 7C; Table S1). The direct role of LIF in Th17 cell
differentiation and STAT3 phosphorylation was confirmed in
parallel experiments with recombinant human LIF (Figure 7D;bsence of LIF (50 ng/ml) under Th17 cell differentiation
entage of Th17 cells and the level of phosphorylated
der Th17 cell differentiation conditions in the presence
the expression of phosphorylated ERK and SOCS3 by
ments (mean and SEM in F).
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Figure 6. Signaling Cascades of LIF Independent of IL-6
(A) Expression of IL-6R and LIFR on purified Il6/ CD4+ T cells stimulated with or without CD3- and CD28-specific antibodies (red or green, respectively) at the
indicated time points.
(B) Purified Il6/ CD4+ T cells were stimulated with CD3- and CD28-specific antibodies in the absence or presence of LIF (50 ng/ml) or IL-6 (20 ng/ml).
Immunoblot analysis of the kinetics of STAT3 phosphorylation in these CD4+ T cells at the indicated time points (left) and the percentage of Th17 cells when these
cells were cultured in the presence of TGF-b (right).
(C) Immunoblot analysis of the levels of phosphorylated STAT3, phosphorylated ERK, and SOCS3 expression in activated Il6/ CD4+ T cells in the presence or
absence of LIF (50 ng/ml).
(D) Purified Il6/ CD4+ T cells were transfected with Socs3-specific or control siRNAs and then treated with or without LIF (50 ng/ml) in the presence of TCR
stimulation. Levels of phosphorylated STAT3 were determined by immunoblotting at the indicated time points.
Data are representative of three independent experiments.
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ation of Th1 or Treg cells from the same CD4+ T cell preparations
(FigureS4). Furthermore, in experimentswithpurifiedCD4+T cells
fromapanelof 18subjectswithMS,LIFwas found tosuppress the
production of IL-17 under Th17 cell differentiation conditions (Fig-
ure 7E). Therefore, human NPC supernatant and recombinant
human LIF had a similar role in the inhibition of Th17 cell differen-
tiation in healthy individuals or MS subjects as it did in EAE.
DISCUSSION
It is generally thought that the therapeutic efficacy of NPCs in
EAE is primarily mediated through a direct neural repair mecha-
nism. Based on this notion, NPC-based cell therapy has been
investigated as a potential treatment modality for MS. Although
there is experimental evidence supporting the repair mechanism
of NPCs in EAE after direct injection into the CNS, the current
hypothesis does not address the possible contribution of a non-280 Immunity 35, 273–284, August 26, 2011 ª2011 Elsevier Inc.neural peripheral mechanism potentially involving immunoregu-
latory mechanism. Here, we provide compelling evidence
showing that when peripherally administered, NPCs have potent
immunoregulatory properties that can account for their treatment
efficacy in EAE, independent of the myelin repair mechanism.
Our experimental systems employed here allow the separation
of anti-inflammatory action from the central myelin repair mech-
anism. This conclusion is supported by the lack of NPCs in the
CNS tissue of treated EAE mice and by the lack of evidence for
myelin repair. The definitive evidence for the peripheral regula-
tory mechanism comes from the observation that the EAE effi-
cacy can be achieved with cell-free supernatant derived from
NPCs or minimally irradiated NPCs that are unable to
differentiate but are capable of secreting cytokines and
neurotrophins.
One of the most challenging aspects of this study was to iden-
tify the critical factor(s) secreted by NPCs responsible for their
treatment efficacy in EAE aswell as the correspondingmolecular
Figure 7. Effect of Human NPC Supernatant and Recombinant LIF on Human Th17 Cells
(A) Concentrations of LIF in the supernatant of human NPC culture measured by ELISA at the indicated time points.
(B) CD4+CD25CD45RAhi naive T cells derived from healthy individuals (n = 15) were cultured under Th17 cell polarization conditions in the presence of human
NPC supernatant at the indicated dilutions and analyzed for the percentage of Th17 cells (top) and the level of phosphorylated STAT3 (bottom).
(C) The percentage of Th17 cells analyzed in the same culture as described above in the presence of a LIF-neutralizing antibody or an isotype control.
(D) The same cell preparations as in (B) were cultured under Th17 cell polarization conditions in the presence of recombinant human LIF at the indicated
concentrations. The percentage of Th17 cells and the level of STAT3 phosphorylation were determined by flow cytometry.
(E) Purified CD4+ T cells fromMS subjects (n = 18) were treated with recombinant LIF under the Th17 cell differentiation conditions. Supernatants were measured
for IL-17 production by ELISA.
*p < 0.05 and **p < 0.01 (two-tailed Student’s t test). Data are representative of and reproducible from at least ten individual specimens (mean and SEM in A and E).
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porting a critical role of LIF in inhibiting Th17 cell differentiation
and in mediating the efficacy of NPCs in EAE. Mouse and human
NPCs used here produce large amounts of endogenous LIF.
Neutralization of LIF in NPC supernatant or administration of
LIF antibody in NPC-treated mice abolished the effects on
Th17 cell differentiation and the efficacy against EAE. Moreover,direct administration of recombinant LIF was efficacious in EAE
and LIF directly inhibited Th17 cell differentiation in both mouse
CD4+ T cells and human CD4+ T cells. This study sheds light on
the critical role of LIF in Th17 cell biology in an autoimmune
disease setting.
It is remarkable that the anti-inflammatory properties of NPCs
and the effects of LIF treatment in EAE mice are mediated notImmunity 35, 273–284, August 26, 2011 ª2011 Elsevier Inc. 281
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selective inhibition of Th17 cell differentiation, sparing Th1,
Treg, and Th2 cells (data not shown). Our study provides
a detailed account of the underlying molecular mechanism and
the key signaling events responsible for the inhibition of Th17
cell differentiation by LIF. In this regard, our in vitro and ex vivo
studies revealed the SOCS3-STAT3 pathway to be the key axis
in the signaling cascade that mediates the inhibition of Th17
cell differentiation in response to LIF treatment. The role of
SOCS3 described here is consistent with previous reports
indicating that SOCS3 deficiency in T cells results in higher
numbers of Th17 cells both in vitro and in vivo (Chen et al.,
2006). Furthermore, the critical involvement of SOCS3 in Th17
cell differentiation offers an explanation for the selective effect
of LIF on Th17 cells, sparing other CD4+ T cell subsets, because
SOCS3 deficiency has no significant effect on Th1 and Th2 cell
differentiation and Treg cells do not express SOCS3 (Chen
et al., 2006; Kinjyo et al., 2006).
How does LIF regulate signaling pathways in CD4+ T cells in
relation to Th17 cell differentiation in the context of the dynamic
expression of LIF receptors? A LIF receptor is composed of
a signaling subunit (gp130) and a specific receptor binding
subunit for LIF (LIFR) (Kristensen et al., 2005). IL-6 receptors
share gp130 with LIF receptors in addition to IL-6R as a specific
subunit (Yu et al., 2007). We provide a compelling account of the
LIF signaling mechanism in relation to that of IL-6 in Th17 cell
differentiation. On one hand, IL-6 signals through gp130 and
induces STAT3 phosphorylation by recruiting JAK1, JAK2, and
tyrosine kinase 2 (Tyk2) (Heinrich et al., 2003), leading to the
Th17 cell differentiation. On the other hand, through the inducible
and progressive expression of LIFR during Th17 cell differentia-
tion, LIF triggers an inhibitory signaling cascade by upregulating
ERK and SOCS3 activities. The interaction of LIF signaling with
IL-6-induced events leads to the inhibition of STAT3 phos-
phorylation and Th17 cell differentiation. It is conceivable that
LIF may act through the recruitment of SH2 domain-containing
protein-tyrosine phosphatase (SHP2) to activate the ERK
pathway because SHP2 functions as an adaptor by linking
growth factor receptor-bound protein 2 (Grb-2) in the process
(Clahsen et al., 2005).
How do our findings reconcile with the previous observations
that LIF independently induces STAT3 phosphorylation in some
other cell types? In short, our study has confirmed that, in the
absence of IL-6, LIF induces STAT3 phosphorylation in CD4+
T cells immediately after TCR stimulation, at which time the
opposing signaling mediated through ERK and SOCS3 is not
fully initiated. However, the initial STAT3 phosphorylation
induced by LIF is rapidly suppressed by the opposing signaling
dominated by SOCS3 at the later time points. Therefore, our
findings explain why the transient STAT3 phosphorylation is
neither sustainable nor sufficient to induce the Th17 cell
phenotype. This phenomenon of the transient induction of
STAT3 phosphorylation has also been seen in mouse ESCs
(Boyle et al., 2009; Forrai et al., 2006).
The discovery described here supports LIF as a potential
therapeutic target for MS. The potential therapeutic advantage
of LIF stems from its dual action involving an immunoregulatory
mechanism observed in both EAE mice and MS-derived T cells
(as described here) and a neural repair mechanism previously282 Immunity 35, 273–284, August 26, 2011 ª2011 Elsevier Inc.reported by Kilpatrick and colleagues (Slaets et al., 2010). In their
studies with both EAE and a chemically induced demyelination
model, a significant fraction of the peripherally administered
LIF was shown to reach the CNS compartment, corresponding
to the reduction in the EAE severity and the extent of demyelin-
ation by enhancing oligodendrocyte survival (Butzkueven et al.,
2002; Marriott et al., 2008). It is conceivable that both mecha-
nisms induced by LIF can work synergistically to achieve desir-
able therapeutic effects in MS in which the CNS pathology
involves both inflammation and demyelination. This therapeutic
advantage of LIF is rare among the current MS therapies and is
urgently needed for the development of a more effective
disease-modifying treatment for MS.EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice were purchased from Shanghai Laboratory Animal Center.
Ifng/ and Il6/ mice were from the Jackson Laboratory. Stat1/ mice
were purchased from Taconic. All experiments were performed with mice
6–10 weeks old with protocols approved by the Institutional Animal Care
and Use Committee.Neural Progenitor Cell Culture and Supernatant Preparation
Colonies of undifferentiated mouse ESCs (C57BL/6 mouse line) were gener-
ously provided by Y. Jin (Chinese Academy of Sciences) and cultured in
LIF-supplemented mouse ESC medium (Ogawa et al., 2007). Differentiation
and culture of ES-derived NPCs were described in detail in Supplemental
Experimental Procedures. For irradiated NPCs, NPCs were irradiated
(18 Gy) to render them incapable of differentiation. Human NPCs derived
from hESCs (H9 cell line) were purchased from Invitrogen (N7800-100) and
cultured according to the manufacturer’s instructions. Supernatant of both
mouse and human NPCs was harvested at 24 hr, 48 hr, and 72 hr from NPC
cultures at a cell density of 1 3 106 cells/ml.Induction and Treatment of EAE
EAE was induced by complete Freund’s adjuvant-MOG35-55 peptide immuni-
zation and scored daily (Wang et al., 2007). For a prevention protocol, NPCs or
irradiated NPCs were intravenously injected into mice on the day of immuniza-
tion (23 106 cells per mouse). NPC supernatant or control medium (200 ml per
mouse) preincubated with LIF-neutralizing antibody (10 mg per mouse, R&D
systems) or an isotype control antibody (10 mg per mouse, Jackson
ImmunoResearch) was intraperitoneally injected into mice every other day
starting from the day of immunization. LIF-neutralizing antibody or isotype
control antibody was administrated intraperitoneally into NPC-treated or
control EAE mice every other day, starting from the day of immunization. For
a therapeutic protocol, NPCs (23 106 cells per mouse) were intravenously in-
jected into EAE mice on day 10 postimmunization. Recombinant mouse LIF
(Millipore) was injected intraperitoneally into mice every day, starting from
the day of immunization (per prevention protocol) or from day 10 postimmuni-
zation (per therapeutic protocol).Histology and Immunofluorescence
Spinal cords from treated or control EAE mice were fixed in 4% paraformalde-
hyde and paraffin embedded. Sections of 5 mm were stained with Luxol fast
blue or H&E. Tissue sections of brains, spinal cords, and peripheral lymphoid
organs (spleen and lymph nodes) were obtained from EAE mice treated with
Q-dot-labeled NPCs at days 2, 7, 14, 21, and 30 after injection. To enumerate
Q-dot-positive cells, a total of 80 spleen sections, 20 lymph node sections
(4 lymph nodes per mouse), 120 brain sections, and 50 spinal cord sections
were obtained from each mouse at 25 mm intervals and analyzed by fluores-
cence microscopy. Undifferentiated NPCs were stained for Nestin and Sox2
(Chemicon), and after 7 days of differentiation, NPCs were stained for Tuj-1,
CNPase, and GFAP (Chemicon).
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For recall experiments, splenocytes were stimulated with MOG35-55 (20 mg/ml)
or ConA (2 mg/ml) 3 days prior to 18 hr pulse with [3H]-thymidine. For Treg cell
suppression assays, freshly isolated splenic CD4+CD25 T cells from EAE
mice were used as responder (4 3 104 cells/well) and cultured with 2 mg/ml
ConA and 8 3 104 irradiated (18 Gy) syngeneic splenic APCs from EAE mice
in the absence or presence of CD4+CD25+ Treg cells at a density of 4 3
104/well. During the last 18 hr, cells were pulsed with [3H]-thymidine before
harvest. Supernatants from MOG-restimulated or NPC cultures were har-
vested and levels of cytokines or LIF production were measured by ELISA
Kits (R&D Systems).T Cell Purification
CD4+ T cells were purified by a CD4 Negative Isolation Kit (Miltenyi Biotec),
and CD4+CD25 T cells were further prepared by FACS sorting from
MACS-sorted CD4+ T cells. CNS-infiltrating mononuclear cells from EAE
mice were prepared by Percoll gradient separation (Wang et al., 2006). Periph-
eral blood mononuclear cells were obtained from patients (n = 18) with clini-
cally defined MS or healthy volunteers (n = 15) after informed consent and
the protocol was approved by the Institutional Review Board at Baylor College
of Medicine and Institute of Health Sciences. CD4+CD45RAhiCD25 naive
T cells were sorted by FACS.In Vitro T Helper Cell Differentiation
Purified CD4+CD25 T cells were stimulated with antibodies to CD3 (5 mg/ml)
and CD28 (2 mg/ml) under Th17 cell differentiation conditions (rmIL-6, 20 ng/
ml; R&D Systems; rhTGF-b1, 3 ng/ml; anti-IL-4, 10 mg/ml; and anti-IFN-g,
10 mg/ml; BD Biosciences), Th1 cell differentiation conditions (rmIL-12,
10 ng/ml and anti-IL-4, 10 mg/ml; BD Biosciences), Th2 cell differentiation
conditions (rmIL-4, 20 ng/ml; rmIL-2, 10 ng/ml; R&D Systems and anti-IFN-g,
10 mg/ml; BD Biosciences), or Treg cell differentiation conditions (rhTGF-b1,
5 ng/ml and rmIL-2, 40 ng/ml; R&D Systems) in the presence or absence of
NPC supernatant or recombinant mouse LIF (50 ng/ml). In some experiments,
T cell preparations were preincubated with specific inhibitors (PD98059 or
Stattic, Calbiochem) for 1 hr.
CD4+CD45RAhiCD25 naive T cells prepared from healthy individuals were
differentiated into Th17 cells as previously described (Yang et al., 2008a).
CD4+ T cells prepared from MS subjects were stimulated with a cocktail
containing rhIL-6 (50 ng/ml), rhIL-1b (10 ng/ml), and rhIL-23 (20 ng/ml) plus
antibodies to IFN-g and IL-4 (10 mg/ml). Human NPC supernatant or recombi-
nant human LIF expressed by HEK293 cells (293-6E) were added when
indicated. In some experiments, mouse NPC supernatant or human NPC
supernatant was preincubated with LIF-neutralizing antibodies (10 mg/ml) or
isotype control for 1 hr prior to adding into culture.Immunoblotting
CD4+ T cells from lymph nodes of EAEmice or in vitro differentiated Th17 cells
were lysed in ice-cold buffer containing a protease inhibitor cocktail (Roche).
The lysates were fractionated by SDS-PAGE and analyzed by immunoblotting
with specific antibodies to phospho-Jak2, Jak2, phospho-Tyk2, Tyk2, phos-
phor-STAT1, STAT1, phospho-STAT3, STAT3, phospho-STAT6, STAT6,
phosphor-ERK, ERK, SOCS3 (Cell Signaling Technology), and b-actin (Sigma).siRNA Transfection
Purified CD4+ T cells were transfected with Socs3, Lifr, or nontargeting control
siRNAs with a Mouse T Cell Nucleofector Kit (Amaxa, Germany) according to
the manufacturer’s instructions. Mouse Lifr, Socs3, and nontargeting control
siRNAs were from Dharmacon. Gene expression analysis was assessed by
real-time PCR with SYBR Green Master Mix under standard thermocycler
conditions (Applied Biosystems). Gene expression was normalized to the
Actb reference gene.Statistical Analysis
Statistical significance was determined by performing a two-tailed Student’s
t test. p values < 0.05 were considered significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at
doi:10.1016/j.immuni.2011.06.011.
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